Cribado de virus de hepatitis B en mujeres embarazadas: inmigrantes, y chilenas con conductas de riesgo. Manejo del binomio madre-hijo: Plan piloto / Screening of hepatitis B in high risk Chilean and immigrant pregnant women: management of mother to child transmission

Resumen Introducción: Chile es un país de baja endemia de virus de hepatitis B (VHB), pero los países de mayor flujo migratorio hacia Chile tienen una endemia intermediaalta. La inmunoprofilaxis (IP) en el recién nacido (RN) es fundamental para evitar la transmisión vertical de VHB. Objetivos: Determinar la prevalencia de HBsAg en mujeres embarazadas: inmigrantes, y chilenas con conductas de riesgo (CR), y evaluar el cumplimiento de la indicación de IP a los RN de madre con HBsAg reactivo. Material y Métodos: Cohorte prospectiva de cribado de HBsAg a mujeres embarazadas inmigrantes, y chilenas con CR, entre julio 2017 y junio 2018 en CABL. Los RN de madre con HBsAg reactivo se les administró IP adecuada (antes de 12 h de vida). Resultados: Se realizó un total de 1.415 HBsAg: 1.265 a inmigrantes y 150 a chilenas con CR. Se obtuvieron 37 pacientes con HBsAg reactivos. Dos falsos positivos. La prevalencia HBsAg en inmigrantes fue 2,7% y 0,66% en chilenas con CR (p < 0,05). El 91,1% provenía de Haití, con una prevalencia de 3,5% en nuestra área. Todos los RN (36) recibieron IP. La mediana de administración de IP fue 3:02 h. Conclusiones: La prevalencia de VHB en mujeres gestantes inmigrantes fue superior a lo reportado en la población general y en mujeres chilenas con CR. Planteamos la necesidad de implementar el cribado universal en el embarazo, y en especial, en mujeres embarazadas provenientes de países con endemia intermedia-alta.

Background: Chile is a low-endemic HBV country, but countries with the highest migratory flow to Chile have an intermediate-high endemicity. In order to avoid vertical transmission of HBV, immunoprophylaxis (IP) in the newborn (NB) is a key factor. Aim: To identify HBsAg prevalence in pregnant immigrants and Chilean pregnant women with risk behaviors (RB) and to asses IP use in the NB. Material and Methods: Prospective HBsAg screening cohort of immigrant and Chilean pregnant women with RB, between July 1, 2017 and June 30, 2018 in CABL. IP of all NB of reactive HBsAg mothers was assessed. Results: 1,415 HBsAg samples, 1,265 immigrants and 150 Chileans with RB. 37 reactive HBsAg. Two false positive. HBsAg prevalence in immigrant pregnant women was 2.7% and 0.66% in Chileans with RB (p < 0.05). 91.1% came from Haiti, with a prevalence of 3.5% in our region. All NB (36) received IP with a median of administration of 3:02 h. Conclusions: The prevalence in immigrant pregnant women was higher than that reported in the general population and in Chilean women with RB. We proposed the need for universal screening in pregnancy, especially in pregnant women from countries with intermediate-high endemicity.

Detection of occult hepatitis B in serum and oral fluid samples

In occult hepatitis B infection (OBI), hepatitis B virus DNA (HBV DNA) can be detected in serum samples; however, oral fluid collection for detection of HBV DNA has not yet been explored, despite the availability of collection devices. Serum and oral fluid samples from 45 hepatitis B core antibody (anti-HBc)-positive patients were collected for the amplification of the HBV polymerase gene. HBV DNA was detected in five serum and four oral fluid samples (the detection limit for oral fluid was 1.656 log IU/mL in paired serum). In conclusion, simple methodologies of sample collection and in-house polymerase chain reaction (PCR) allowed detection of HBV DNA, and these could be used to improve the diagnosis of OBI, especially in locations with limited resources.

Hepatitis C and hepatitis B virus infections in the etiopathogenesis of pemphigus

BACKGROUND: Previous studies have shown that some viral infections may be triggers for autoimmune diseases. The role of viral infections in the etiopathogenesis of pemphigus has also been investigated. OBJECTIVES: To investigate the relationship between pemphigus and the hepatitis B and C virus infections. METHODS: This retrospective study included 62 patients with pemphigus and 50 healthy controls of matching ages and genders. The control group included relatives who accompanied the orthopedic patients to the hospital but had no history of systemic and/or autoimmune diseases. RESULTS: The group of patients with pemphigus was composed of 43 (69.3%) females and 19 (29.7%) males, and the mean age was 48.08 ± 15.38. The hepatitis C virus antibody was negative in all of the patients. Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), or both, were studied in 44 of the 62 patients. Two (4.3%) of these patients were positive for HBsAg and found to have HBV infection. Fourteen of them were HBsAb positive. Two (4%) of the 50 control subjects showed hepatitis C virus antibody positivity, while only 1 (2%) patient with pemphigus displayed HBsAg positivity. There was no statistically significant difference between the two groups for hepatitis B and C virus infections. CONCLUSIONS: This study does not support an association between pemphigus and hepatitis B and/or C virus infections. .

Hepatitis B and C virus infection among Brazilian Amazon riparians / Infecção pelo virus da hepatite B e C em ribeirinhos da Amazônia brasileira

INTRODUCTION: Viral hepatitis is a major public health concern in Brazil. There are few past studies on this issue, especially among riparian communities. This study aims at determining the seroprevalence of viral hepatitis B and C in the riparian community of Pacuí Island, within the Cametá municipality of Pará State, Brazil. Moreover, this study aims to investigate the principal risk factors that this community is exposed to. METHODS: The current study has accessed blood samples from 181 volunteers who have answered an epidemiological questionnaire. Analyses on serological markers have been tested with commercial ELISA kits for detecting HBsAg, total anti-HBc, anti-HBs, and anti-HCV. Within seroreactive patients for HCV, RT-PCR and line probe assay have been performed to identify the viral genotype. RESULTS: In the serological marker analysis for hepatitis B, no reactivity for HBsAg, rate of 1.1 percent for total anti-HBc, and rate of 19.3 percent for anti-HBs have been observed. On hepatitis C, 8.8 percent seroprevalence has been found, in which 62.5 percent have gotten viral RNA. Among the risk factors studied, the following have been highlighted: non-use of condoms, sharing of cutting instruments, use of illicit drugs, and reports of family disease with HBV or HCV. CONCLUSIONS: The vaccination coverage against HBV is low, and the high prevalence of HCV within this community has been observed.

INTRODUÇÃO: As hepatites virais constituem um importante problema de saúde pública no mundo. No Brasil existem poucos estudos sobre esta questão, especialmente entre as comunidades ribeirinhas. O objetivo deste estudo foi determinar a soroprevalência das hepatites B e C virais na comunidade ribeirinha da Ilha do Pacuí, no Estado do Pará, Brasil, e investigar os principais fatores de risco principal a que está comunidade está exposta. MÉTODOS: O presente estudo avaliou amostras de sangue de 181 voluntários que responderam a um questionário epidemiológico. Análises de marcadores sorológicos foram testados com kits comerciais de ELISA para detecção de HBsAg, anti-HBc total, anti-HBs e anti-VHC. Nos pacientes reagentes para VHC, RT-PCR e um line probe assay foi realizado para identificar o genótipo viral. RESULTADOS: Na análise dos marcadores sorológicos para hepatite B, observou-se taxas de 1,1 por cento para anti-HBc total e 19,3 por cento para anti-HBs, o marcador sorológico HBsAg não foi encontrado nesta população. Para a hepatite C foi encontrada um soroprevalência de 8,8 por cento, destes 62,5 por cento tinham RNA viral. Entre os fatores de risco estudados se destacaram: a não-utilização de preservativos, o compartilhamento de instrumentos cortantes, uso de drogas ilícitas e relatos de doença na família com VHB ou VHC. CONCLUSÕES: Observamos que a cobertura de vacinação contra o VHB é baixa e uma alta prevalência da hepatite C nesta comunidade.

Sclerosed hemangioma of the liver / 대한간학회지

No abstract available.

Revisão sistemática da eficácia do interferon alfa (convencional, peguilado) e lamivudina para o tratamento da hepatite crônica B: [revisão] / Efficacy of interferon (conventional, pegylated) and lamivudine for treatment of chronic hepatitis B: a systematic review: [review]

A hepatite crônica B constitui um grave problema de saúde pública e vem demonstrando crescentes gastos com financiamento de medicamentos de dispensação em caráter excepcional e de alto custo no Sistema Único de Saúde (SUS). O objetivo do estudo foi comparar a eficácia do interferon (convencional; peguilado - PEG2a) e lamivudina (LAM) para o tratamento da hepatite crônica B, pelo método de revisão sistemática selecionando ensaios clínicos randomizados e controlados identificados nas bases PubMed e LILACS. As medidas de resultado consideradas foram resposta virológica, soroconversão, resposta bioquímica, resposta histológica e efeitos adversos. Foram selecionados 35 artigos. A presença ou ausência do HBeAg e os níveis de alanina amino transferase (ALT) no pré-tratamento demonstraram papel fundamental na indicação terapêutica inicial. O tratamento com interferons convencionais permite a inativação da doença por longos períodos de tempo, podendo resultar em soroconversão HBsAg. O PEG 2a demonstrou eficácia superior ao interferon e LAM e efeitos colaterais semelhantes ao interferon. A LAM apresenta vantagem de ser sensível para os pacientes HBeAg negativo e apresenta como maior desvantagem o desenvolvimento de resistência.

Chronic hepatitis B is considered a major public health problem, and its treatment entails increasing health budget expenses with high-cost drugs covered by Unified National Health System. The objective of this study was to compare the efficacy of interferon (conventional; pegylated - PEG2a) and lamivudine (LAM) for the treatment of chronic hepatitis B through a systematic review, selecting randomized, controlled clinical trials identified in PubMed and LILACS. Target outcomes were virological, biochemical, and histological response, seroconversion, and adverse effects. The review selected 35 articles. Presence or absence of HBeAg and pre-treatment alanine aminotransferase (ALT) levels were considered important factors in the initial therapeutic indication. Treatment with conventional interferon enables lasting disease inactivation and can result in HBsAg seroconversion. PEG2a showed better efficacy than interferon and LAM and similar side effects to interferon. LAM presents advantages such as its sensitivity in the HbeAg-negative phenotype, while its main disadvantage is the development of resistance.

Analysis of Clinical Characteristics and S Gene Mutation of Hepatitis B Virus (HBV) in Patients with Hepatitis B Surface Antigen RIA Negative and HBV DNA Positive / 대한진단검사의학회지

BACKGROUND: We investigated hepatitis B virus (HBV) infection cases, who were HBsAg negative by radioimmunoassay (RIA) and HBV DNA positive for their clinical characteristics, the S gene mutation of hepatitis B virus (HBV), and usefulness of other HBsAg immunoassay. METHODS: Among the patients requested for HBV DNA quantification, 16 patients positive in HBV DNA but negative in HBsAg RIA (BNIBT HBsAg Kit, China) were enrolled. The "a" determinant of HBV S gene was sequenced and clinical characteristics were reviewed. Additional HBsAg assay was performed using Architect HBsAg kit (Abbott laboratories, USA) employing chemiluminescent immunoassay method. RESULTS: Eleven of the 16 patients showed multiple mutations in the "a" determinant. These patients received liver transplantation several years ago and have been treated with hepatitis B immune globulin (HBIG) and antiviral drugs. G145R mutation was found in 8 patients and G145K, D144G, and D144A were also frequently found. Among 9 of the 11 patients tested for HBsAg by Architect HBsAg kit, 8 showed positive results. Among 4 of the remaining 5 patients, only 2 showed weak positive results (< or =1 IU/mL) in Architect HBsAg kit. CONCLUSIONS: HBV DNA-positive/HBsAg RIA-negative results were mostly observed in the patients treated with HBIG after liver transplantation, in whom HBIG escape mutations were found. Majority of these cases were positive in Architect HBsAg assay, and it is recommended to use other HBsAg immunoassay methods that are more sensitive than RIA in the detection limit as well as in the detection of escape mutant in hospitals performing liver transplantation.

Tea polyphenols exerts anti-hepatitis B virus effects in a stably HBV-transfected cell line / 华中科技大学学报（医学）（英德文版）

In this study, the anti-HBV effects of tea polyphenols (TP) were examined. After cells were exposed to TP for 3, 6, 9 days, amounts of HBsAg, HBeAg and HBV-DNA released into the supernatant of the cultured HepG2 2.2.15 cells were detected. TP, to some extent, inhibited the secretion of HBsAg and strongly suppressed the secretion of HBeAg in a dose-dependent (P<0.01) and time-dependent manner, with 50% maximal inhibitory concentration (IC50) value being 7.34 microg/mL on the 9th day, but the time-dependence was not significant (P=0.051). Expression of HBV-DNA in the supernatant of the cell culture also was significantly decreased in a dose-dependent fashion (P<0.01). The IC50 of TP in inhibiting HBV DNA was 2.54 microg/mL. It concluded that TP possessed potential anti-HBV effects and may be used as a treatment alternative for HBV infection.

Risk factors for intrafamilial spread of hepatitis B in northeastern Bosnia and Herzegovina

Accurate estimations of hepatitis B virus transmission risk for any region in Bosnia and Herzegovina are not clearly established. We aimed to determine levels of risk associated with intrafamilial transmission of hepatitis B infection within families in our region. Family members of 81 chronic carriers of hepatitis B surface antigen [> 6 months positive and considered as index case] were tested for hepatitis B markers. For family members, we recorded their age, sex, and family relationship to the index case, and vaccination status. The proportion of HBsAg positive family members was 25/207 [12.1%], while the proportion of family members with evidence of exposure to HBV was 80/207 [38.6%]. Only 17/207 [8.2%] family members had eviddence of past HBV vaccination. Age was found to be a significant predictor of HBV exposure of family members [odds ratio 1.05, 95% CI 1.03-1.07, P < .001]. In a multivariate analysis, HBsAg positivity was associated with a female index case [odds ratio 11.31, 95% CI 3.73-34.32, P < .001], HBeAg positivity in the index case [odds ratio 5.56, 95% CI 1.80-17.23, P < .005] and being a mother of the index case [odds ratio 9.82, 95% CI 2.43-39.68, P < .005]. A female index case [odds ratio 4.87, 95% CI 2.21-10.72, P < .001], HBeAg positivity in the index case [odds ratio 3.22, 95% CI 1.15-9.00, P < .05] and being a mother of the index case [odds ratio 3.72, 95% CI 1.19-11.64, P < .05] were also risk factors for HBV exposure among family members. The combination of HBeAg positivity and female index case was a significant predictor for HBsAg positivity of family members [odds ratio 70.39, 95% CI 8.20-604.61, P < .001]. Children of HBeAg positive mothers are at highest risk for becoming chronic carriers themsselves and generally, the combination of female sex and HBeAg positivity dramatically increases the chances of HBV transmission within the family

Current status of liver diseases in Korea: Hepatitis B / 대한간학회지

Hepatitis B virus (HBV) infection is the one of the most common causes of the liver diseases in Korea. Since the discovery of Australia antigen (hepatitis associated antigen, or HBsAg later), hepatitis associated antigen was tested widely. HBsAg was detected in 6.6~8.6% in 1980's. Later, it decreased to 5.7% in 1990's. Remarkably, seropositivity of the children deceased to 0.2% after the nationwide vaccination program. Although hepatitis B vaccines are highly effective, the failure rate of perinatal prophylaxis in babies born to HBsAg positive mother was reported to be 4.25%. Treatment of chronic hepatitis B was initiated after the introduction of interferon alpha. Lamivudine opened a new era of oral antiviral agent, and it has been widely used in Korea since 1999. Adefovir was proven to have a good efficacy for lamivudine-resistant chronic hepatitis B. Newer potent antiviral agents such as entecavir, clevudine, and telbivudine are available currently. Further studies are warranted for understanding factors influencing natural history, improving treatment outcomes, and overcoming vaccine non-response.

HBeAg/anti-HBe, alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers.

Serum samples from a total of 72 chronic hepatitis B virus carriers were analysed by serological, biochemical and molecular assays. The aim was to evaluate the relationship of the serological and biochemical parameters with molecular markers in order to assess the infectivity of virus. Out of 72 chronic HBsAg positive carriers, 28 patients were HBeAg positive and anti-HBe negative, 38 patients were HBeAg negative and anti-HBe positive, only 3 patients were positive for both HBeAg and anti-HBe and the rest 3 patients were negative for both markers. Detectable HBV DNA lcvcl was found in 92.86% HBsAg-positive/anti-HBe negative patients along with raised alanine aminotransferase (ALT) level (67.86%) compared with HBeAg-negative/anti-HBe positive carriers (36.84%) (p value = 0.02) and out a total of 38 HBeAg-negative/anti-HBe positive carriers, 12 (31.58%) patients had detectable lcvel of HBV DNA. Among the 14 HBeAg-negative/anti-HBe positive patients with elevated ALT level, 8 (57.14%) had detectable HBV DNA whereas out of 24 HBeAg-negative/anti-HBe positive patients with normal ALT level only 4 (16.66%) had detectablc HBV DNA lcvel. Significantly high rate of detection of HBV DNA was seen among anti-HBe positive patients with raised ALT level compared with the patients with normal ALT level (p value = 0.01).

Sero-prevalence of immunodeficiency virus, hepatitis B and C and syphilis among blood donors at El Obeid Teaching Hospital, West Sudan

This study aimed to determine the sero-prevalence of transfusion transmitted infections [TTIs], namely immunodeficiency virus, hepatitis B and C and syphilis among blood donors. The study was carried in the blood bank at ElObeid Teaching Hospital. The study included 260 blood donor. Informed consent was obtained from each. Personal and socio-demographic data, information about risk factors such as blood transfusion, sexual partners, intravenous drug usage, tattooing and past history of jaundice all were included in a well designed questionnaire. Screening of blood samples for hepatitis B surface antigen [HBsAg], human immunodeficiency virus [HIV], hepatitis C virus [HCV] and Treponema pallidum antibodies were done using immunochromatographic [ICT] strips. The study included 260 blood donor. All were males. The screening result for antibodies against HIV and Treponema pallidum was positive in 2 [0.8%] and 40 [15%] donors respectively. HBsAg was detected in 26 [10%] donors. Screening result for antibodies against hepatitis C virus was negative in all samples. This study showed that the sero-prevalence of hepatitis B and syphilis was high in our study population. This mandates very strict criteria for selection of blood donors and also methods of laboratory assays for detection of infectious agents must be improved. On the other hand indications for blood transfusion should be restricted

Prevalence of Hepatitis B serological markers among health care workers in Baghdad, Iraq

Most previous studies on the prevalence of hepatitis B markers among Iraqi health care workers [HCW's] were limited to detection of HBsAg and anti-HBs antibodies. This work is a comprehensive one carried out to determine the prevalence of serological markers of HBV among a sample of Iraqi HCW's, and to elucidate the effect of various health professions, duration of professional practice, and the practice in different hospitals on exposure to HBV. A total of 1656 HCW's selected from various hospitals and medical units in Baghdad, together with 238 apparently healthy subjects [as control group] were screened for HBsAg and anti-HGs antibodies in the period from June 1995 to April 1998.All HBsAg positive subjects [HCWs and controls] were tested for anti-HBc [IgM], HBeAg and anti-HBe. Serum testing was carried out by enzyme-linked immunosorbent assay [ELISA]. A higher rate of HBsAg [5.4%] was observed among HCW's than controls [3.4%]. A significantly higher prevalence rate of anti-HBs antibodies in HCW's [39.3%] than controls [24.4%] was demonstrated. A significant difference in the prevalence of HBsAg was detected in the renal dialysis group only when each group was compared with the controls. The frequency of HBV infection was more than two times higher in HCW's with more than twenty years duration of professional practice compared to those with less than one year duration of practice. The lowest rate of HBsAg was seen among HCW's in general hospitals [4.8%], wherase the highest rate seen among those infectious diseases hospitals [9.0%]. HCW's still represent a high-risk group for HBV infection, and they may act as a potential source of infection to their contacts. Therefore vaccination of HCW's should be vigorously applied

Correlative analysis of histological profile of the adjoining liver parenchyma with liver enzyme levels in hepatocellular carcinoma and their comparison with chronic liver disease in autopsy cases.

The exact mechanism and aetiological factor for hepatocarcinogenesis is not yet well defined. Besides genomic integration of hepatitis B viral particles, persistent chronic inflammation is postulated to be important initiating factor in viral related hepatocellular carcinoma (HCC). The objectives of the present study were--to correlate histological profiles of chronic liver disease in the adjoining non-tumor liver tissue in HCC with liver enzymes, to compare with those of non-carcinomatous chronic liver disease cases using the liver tissue and data collected at autopsy, and to correlate with hepatitis B and C positive status. Post mortem liver and data available at autopsy were used for the study. Changes of chronic liver disease was graded and staged according to Peter Scheur's (1991). In HCC, the non-malignant liver tissue was used for the study. Hepatitis B surface and core antibodies were demonstration by immunohistochemistry. HCV was documented by RT-PCR using the tissue extract of paraffin embedded liver tissue. HCC group had higher inflammatory grading and transaminases levels than non-HCC group. HBcAg alone and dual HBcAg and HCV positive cases were more in HCC group. Incidence of biliary epithelial cell injury was higher in HCV positive subgroup. Conclusion: higher incidence of inflammatory grading and enzyme level in alone HBcAg and dual HBcAg and HCV positivity in HCC group would suggest significant role of ongoing persistent chronic inflammation and actively replicating HBV and HCV infections in carcinogenesis.

Hyperendemic foci of hepatitis B infection in Arunachal Pradesh, India.

AIM: To study the prevalence of hepatitis B virus (HBV) infection among an isolated tribe of Northeast India that migrated long back from Tibet. METHODS AND MATERIALS: Randomly selected 438 subjects from Idu Mishmi tribe of Arunachal Pradesh were screened for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), envelope antigen (HBeAg) using ELISA kits. RESULTS: The point prevalence of HBsAg was found to be 21.2% (93/438). Anti-HBc prevalence was 92.3% (193/209). Anti-HBs above 10 IU/ml were detected in 48% (96/200). Prevalence of HBeAg was higher (42.1%, 16/38) in children (less than 15 years) compared to adolescent and adults (32.7%, 18/55). History of hepatitis was significantly associated with positive HBsAg status (p < 0.000). CONCLUSION: Hepatitis B virus infection is hyperendemic among Idu Mishmi tribe of Arunachal Pradesh, India. Though, the route of transmission could not be ascertained, but the high HBV infection (78.6%) among less than 5 yrs and the finding of 58.4% of HBsAg positive mothers bearing HBsAg positive child indicates possibility of vertical transmission in this setting.

Resposta à vacinação contra a hepatite B em alcoolistas sem cirrose hepática clinicamente evidente / Response to hepatitis B vaccine in alcoholics without clinically evident liver cirrhosis

RACIONAL: Alcoolistas têm maior prevalência de infecção pelo Vírus da hepatite B (VHB), o que aumenta os riscos de desenvolverem cirrose hepática e/ou hepatocarcinoma. OBJETIVO: Avaliar a resposta à vacinação contra o VHB em alcoolistas sem cirrose hepática. MÉTODOS: Foram vacinados 20 homens alcoolistas, com idade média de 46,6 ± 10,9 anos, que bebiam mais de 80 g de etanol por dia, por mais de 10 anos. O grupo controle, 40 homens não-alcoolistas, tinha idade média de 37,8 ± 9,7 anos. Nenhum dos indivíduos tinha evidências sorológicas de contato com o VHB ou com os vírus da hepatite C e o da imunodeficiência humana. A vacina Euvax B, 20 µg, foi aplicada na região deltóide, em 0, 1 e 6 meses. Após 1 mês da última dose foi determinado o anti-HBs sérico e considerado não-respondedor aqueles com níveis <10 mUI/mL, soroconvertidos entre 10 e 99 mUI/mL e soroprotegidos >100 mUI/mL. RESULTADOS: Não houve diferença significante nas respostas entre alcoolistas e controles, respectivamente, na freqüência de não-respondedores (35,0 por cento vs 32,5 por cento), soroconversão (15,0 por cento vs 15,0 por cento) e soroproteção (50,0 por cento vs 52,5 por cento). Os níveis médios de anti-HBs nos alcoolistas que responderam à vacina (511 ± 448 mUI/mL) foram semelhantes aos dos controles (696 ± 410 mUI/mL). Não foram observadas interferências negativas em relação ao índice de massa corpórea, ao tabagismo, continuar bebendo e da coexistência de pancreatite crônica sem insuficiência pancreática. CONCLUSÕES: Homens alcoolistas sem cirrose hepática respondem à vacina contra o VHB com freqüência e níveis séricos de anti-HBs semelhantes aos não-alcoolistas.

BACKGROUND: Alcoholics have higher prevalence of hepatitis B virus (HBV) infection than non-alcoholics and such fact may influence in the development of liver cirrhosis and/or hepatocellular carcinoma. AIM: To evaluate the response to hepatitis B vaccine in alcoholics without liver cirrhosis. METHODS: Twenty male alcoholics with mean age of 46.6 ± 10.9 years were vaccinated; they ingested more than 80 g of ethanol/day for more than 10 years. As control group 40 male non-alcoholics with mean age of 37.8 ± 9.7 years were also vaccinated. No serological evidence of contact with HBV, hepatitis C virus or human immunodeficiency virus was found among the subjects of both groups. The vaccine Euvax B (20 µg) was administered intramuscularly into the deltoid area at 0, 1 and 6 months. Serum anti-HBs were determined after one month of the last dose. Levels <10 mUI/mL were considered as non-response, between 10 and 99 mUI/mL as seroconversion, and > 100 mUI/mL as seroprotection. RESULTS: No significant difference was found between alcoholics and controls, respectively, in the frequency of non-response (35.0 percent vs 32.5 percent), seroconversion (15.0 percent vs 15.0 percent) and seroprotection (50.0 percent vs 52.5 percent). Among responders, mean levels of anti-HBs in alcoholics (511 ± 448 mUI/mL) were similar to the controls (696 ± 410 mUI/mL). No negative interference on the response was associated with the body mass index, tabagism, being drinking or concurrent chronic pancreatitis without pancreatic insufficiency. CONCLUSIONS: Male alcoholics without liver cirrhosis had similar frequency and serum levels of anti-HBs to the non-alcoholics in response to HBV vaccination.

Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.

BACKGROUND: Prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) markers including active and occult infection has not been described in diverse cohorts among HIV-infected patients in India. Earlier studies have explained the role of HBV/HCV co-infection in cohorts of injection drug users (IDUs) but the sexual co-transmission of HBV/ HCV is not completely understood. OBJECTIVE: The objective of this study was to assess the prevalence of occult HBV & HCV infection in HIV positive sexually acquired transmission risk group. MATERIALS AND METHODS: 58 sexually acquired HIV positive patients were taken up for the study of occult HBV/HCV co-infection. Data on demographics, sexual behaviour, sexually transmitted diseases (STD), medical history, laboratory tests viz., serum ALT and CD4 count were recorded. HBV serology included HBsAg, anti HBs, IgG anti HBc and HBV DNA (PCR). HCV serology included anti HCV & HCV RNA (RT-PCR). RESULTS: Occult HBV infection (HBV DNA) was observed in 12.2% (7/58 with HBsAg -ve and IgG anti HBc +ve subjects) while an overall prevalence of HBV DNA was 13.7% (12% occult & 1.7% in HBsAg+ve patients). Out of 58 HIV positive patients 29.3% demonstrated reactivity for any marker of past or current HBV infection. (HBsAg 1.7%, anti HBs 10.3% anti HBc IgG 17.2%). 4/58 (6.8%) revealed anti HCV positivity along with HCV RNA positivity by RT-PCR while 6/58 (10.3%) individuals revealed an occult HCV infection (anti HCV negative). The overall HCV RNA prevalence was 17.2%. 2 out of 58 (3.4%) individuals were positive for occult infection of both HBV DNA & HCV RNA (Triple infection HIV/HBV/ HCV). The HBV/HCV co-infected group (n = 18) showed a significantly high ALT (114.3 + 12.3 U/I) & low CD4 count (202.5 + 33.7 cells/mm3). The percent prevalence of HBV/ HCV co-infection was higher in the illiterate group, in men less than 30 years of age, and in those who were married and exhibited polygamous activity. CONCLUSIONS: The study demonstrated that in HIV infected patients testing only serological viral markers like HBsAg, antiHBcIgG & anti HCV, fails to identify the true prevalence of co-infection with HBV & HCV. Qualitative PCR for HBV DNA & HCV RNA detects co-infection in patients who are negative for serological markers. Also, in subjects who had only a sexual risk factor for parenterally transmitted infections, HIV may enhance the sexual transmission of HBV and HCV.

Comparative analysis of HBV and HCV infection in hepatocellular carcinoma and chronic liver disease--an autopsy based study.

Hepatocellular carcinoma (HCC) is one of the common malignancies worldwide including Asian countries. Chronic viral hepatitis is implicated as an important etiological factor in carcinogenesis of liver. AIM: To study incidence of hepatitis B (HBV) and C (HCV) viruses in HCC and to compare the incidences with that of chronic liver disease. MATERIALS AND METHOD: 40 cases each of HCC (group I) and chronic liver disease including cirrhotic liver (group II) who died of the liver disease. All cases were stained with HBsAg and HBcAb for HBV and RT-PCR for HCV RNA. Different groups were compared using student's t-paired and chi-square tests. RESULTS: Group I--HCC was seen in 37 cirrhotics and 3 non-cirrhotic cases. HBsAg was positive in 32 cases (80%), HBcAb in 22 cases (55%) and HCV in 23 cases (57.5%) (p<0.05). Dysplastic nodule (DN) was seen in 25 cases, HBsAg and HBcAg positivity were seen in 18 and 15 cases respectively. Group II--32 cases were cirrhotic and 8 were non-cirrhotics. HBsAg was positive in 28 (70%), HBcAb in 12 (30%) and HCV in 18 (45%) cases. DN was seen 24 cases, HBsAg and HBcAg postiviy were seen in 16 and 7 cases respectively. HBV and HCV co-infection was seen in 20 and 15 cases, and HCV with HBcAb positivity was seen in 13 and 9 cases in groups I and II respectively. Number of cells in each case showing positivity for HBcAb was also significantly higher in group I (p<0.01). Age and sex distribution did not show any distinctive differences between the two groups. CONCLUSION: the study highlights a high incidence ofHBVand HCV infection in cases of chronic liver disease and HCC. HBcAb positive state appears to be an independent risk factor for HCC.

Prevalência ambulatorial em um hospital geral de marcadores para hepatites B e C em pacientes com infecção pelo vírus da imunodeficiência humana / Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital

RACIONAL: Os vírus das hepatites B (VHB) e C (VHC) e da imunodeficiência humana (HIV) utilizam a mesma rota de transmissão, sendo a prevalência de VHB e VHC em pacientes infectados pelo HIV maior do que aquela encontrada na população em geral. OBJETIVO: Determinar a prevalência de marcadores para hepatites B e C em uma população de pacientes com HIV, bem como os fatores de risco envolvidos. PACIENTES E MÉTODOS: Dentre os 5 870 prontuários de pacientes com HIV em acompanhamento no Serviço de Infectologia do Hospital Nossa Senhora da Conceição, Porto Alegre, RS, foram aleatoriamente selecionados 587 prontuários. Destes, foram considerados para análise retrospectiva aqueles em que havia sido pesquisado algum marcador para hepatites B (HBsAg, anti-HBc ou anti-HBs) ou C (anti-VHC), perfazendo o total de 343 pacientes. RESULTADOS: O HBsAg foi positivo em 14 de 306 (4,6 por cento) pacientes, anticorpo anti-HBs, em 40 de 154 (26,0 por cento) pacientes, e anti-HBc em 79 de 205 (38,5 por cento) pacientes. Dentre aqueles que realizaram anti-VHC, 126 de 330 (38,2 por cento) tinham-no positivo. Co-infecção por vírus B e C foi observada em 7 dentre os 296 pacientes que realizaram tanto o HBsAg, quanto o anti-VHC (2,4 por cento). Dentre aqueles HBsAg positivos, a principal categoria de exposição foi o relacionamento homossexual masculino (50,0 por cento). Dentre aqueles anti-VHC positivos, a principal categoria de exposição foi o uso de drogas ilícitas injetáveis (75,3 por cento). Naqueles monoinfectados com HIV (185 pacientes), o fator de risco mais prevalente foi relacionamento heterossexual promíscuo ou com cônjuge infectado por HIV em 83 pacientes (44,9 por cento). CONCLUSÃO: Em nosso meio, as co-infecções VHB-HIV e VHC-HIV são freqüentes, sendo observado maior impacto na associação do VHC com o HIV.

BACKGROUND: Hepatitis B and C viruses and human immunodeficiency virus share the same route of transmission, and the prevalence of HBV and HCV infection in patients infected with HIV is greater than it is in the general population. AIM: To determine the prevalence of hepatitis B and C markers in a population of patients with HIV as well as the risk factors involved. PATIENTS AND METHODS: From 5,870 registration forms of patients with HIV of an Infectology Unit, 587 were randomly selected. From these, the 343 which had investigated the presence of any hepatitis B (HBsAg, anti-HBc or anti-HBs) or C (anti-HCV) marker were retrospectively analyzed. RESULTS: HBsAg was positive in 14/306 (4.6 percent), anti-HBs was positive in 40/154(26.0 percent), and anti-HBc in 79/205 (38.5 percent). The anti-HCV test was reactive in 126/330 (38.2 percent). HBV and HCV co-infection was observed in 7 of the 296 patients who had both HBsAg and anti-HCV tests (2.4 percent). For those who were HBsAg positive, the main exposure factor was homosexual intercourse (50.0 percent). For those who were anti-HCV reactive, the main risk factor was intravenous drug use (75.3 percent). In the HIV mono-infected (185 patients), the most prevalent exposure risk factor was promiscuous heterosexual practices or sexual intercourse with a spouse infected with HIV (83 patients - 44.9 percent). CONCLUSION: In our environment HBV-HIV and HCV-HIV co-infections are frequent, a greater relevance being observed in the association between HCV and HIV.